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Abstract: Malignant ascites is the abnormal accumulation of fluid in the peritoneal cavity 
associated with several intrapelvic and intra-abdominal malignancies. The development of 
ascites leads to significant symptoms and poor quality of life for the cancer patient. Available 
therapies for palliation include treatment of the underlying disease, but when there are no 
treatment options, the use of diuretics, implantation of drainage catheters, and surgical shunt-
ing techniques are considered. None of these symptom palliation options affect the course of 
disease. The development of trifunctional antibodies, which attach to specific overexpressed 
surface markers on tumor cells, and trigger an immune response leading to cytoreductive effects, 
represents a new approach to the management of malignant ascites. The purpose of this review 
is to highlight current therapies for malignant ascites and review data as to the effectiveness of 
a new trifunctional antibody, catumaxomab.
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Introduction
Malignant ascites is the abnormal accumulation of fluid in the peritoneal   cavity 
  associated with several intrapelvic and intra-abdominal malignancies. When   occurring 
in a setting other than ovarian cancer, malignant ascites is associated with a poor 
  prognosis1 and impacts the remaining days of patients lives by contributing to   symptom 
burden, causes frequent and unnecessary hospitalization, and leads to poor quality 
of life.2 Palliative options that have been used for malignant ascites have included 
fluid restriction, diuretics, peritoneal-venous shunts, and most recently the Food and 
Drug Administration (FDA) approved PleurX®   catheter.3 Most of these therapies are 
not uniformly successful or are associated with adverse effects which limit their use. 
More options are needed for palliation. The development of monoclonal   technologies 
as well as advances in basic science cancer research have identified potential targets 
for monoclonal therapies and have initiated the use of monoclonal therapies for 
the treatment of malignant ascites. Catumaxomab4   represents a new advance in the 
  management of malignant effusions. A   trifunctional molecule, this monoclonal anti-
body targets overexpressed epithelial markers   associated with   malignancies which 
are commonly associated with malignant ascites, and   harnesses the immune system 
to target the immune-mediated destruction of tumor cells   causing ascites. This article 
reviews relevant therapies for malignant ascites and also   illustrates how new therapies 
such as catumaxomab may play a role in the palliation of malignant ascites.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Epidemiology
The malignancies most commonly associated with malignant 
ascites include the gynecologic malignancies,   gastrointestinal 
malignancies, as well as breast cancer and carcinoma of unknown 
primary. Among the gynecologic malignancies, ovarian carci-
noma predominates. Of the gastrointestinal   malignancies, ascites 
can occur with advanced colon,   pancreas, gastric carcinoma, 
and esophageal carcinoma. One   retrospective review5 of causes 
of malignant ascites found that ovarian cancer had the highest 
proportion of patients who developed ascites at 37.7%, followed 
by pancreaticobiliary cancers (21%), gastric cancer (18.3%), 
esophageal cancer (4.0%), colorectal cancer (3.7%), and breast 
cancer (3.0%). This particular series had a low incidence of 
ascites associated with hepatocellular   carcinoma. The study also 
found that the   number of cases of malignant ascites due to an 
unknown primary cancer was only 8.1% compared to   previous 
reports. Previous estimates also suggest that up to 20% of cases 
of carcinoma of unknown   primary have been associated with 
ascites.5 Advances in   imaging and immunocytochemical   analysis, 
with the result being better tumor identification, will continue to 
influence a decline in the number of cases of malignant ascites 
associated with carcinoma of unknown primary.
Pathophysiology
While the pathophysiology of malignant ascites is not totally 
understood, factors that contribute to the development of 
ascites include lymphatic obstruction by tumor cells, excess 
vascular permeability, and hormonal effects, as well as other 
  tumor-specific effects such as excess metalloproteinase 
  production.6 The ability of positive cytology to obstruct   draining 
catheters testifies to the potential effect of tumor cells on smaller 
lymphatic channels. Increases in vascular   permeability have 
received much attention as factors causing malignant ascites. In 
particular, vascular endothelial growth factor (VEGF) has not 
only been implicated as a factor for tumor growth, but VEGF 
has also been cited as an important factor affecting vascular 
permeability, a key factor in ascites production.7 VEGF is a 
potent growth factor that stimulates blood vessel formation as 
well as exerting effects on the vascular   endothelial cell. A potent 
permeability factor, it is 50,000 times as potent as histamine.8 
VEGF plays a role in the pathophysiology of malignant ascites 
with malignant cells overexpressing VEGF and producing high 
levels in ascitic fluid.9 High levels of VEGF are found in the 
malignant   effusions of ovarian,   colorectal, and breast cancer 
patients.9 In preclinical models, the   administration of malignant 
ascitic fluid to animals without malignant ascites can cause 
malignant ascites.10 Blockade of VEGF with a   monoclonal 
antibody can reverse the   severity of ascites in animal models.11 
VEGF levels respond to therapy and are lowered with chemo-
therapy treatments of malignancy.12   Hormonal mechanisms 
have been implicated and may play a role in the development of 
ascites as some cases of malignancy associated ascites respond 
to diuretics, in   particular those cases with elevated renin levels.13 
Matrix metalloproteinases are also postulated to influence the 
  development of malignant ascites. They degrade the   extracellular 
matrix and facilitate the spread of tumors, undoubtedly contrib-
uting to tumor-related increases in permeability. Inhibitors of 
metalloproteinases can cause formation of ascites.14
Symptoms
Ascites can cause significant symptoms referable to the gas-
trointestinal and genitourinary tract. Common   gastrointestinal 
symptoms include distension, nausea, and vomiting. Patients 
experience dyspnea, as well as weight gain and edema. One 
survey15 of symptoms from women with ovarian cancer 
describe bloating, swelling, fatigue, urinary frequency, con-
stipation, abdominal and pelvic pain, back pain, anorexia, and 
vaginal bleeding, as well as gastrointestinal symptoms such 
as indigestion, constipation, abdominal cramping, diarrhea, 
gas, or movement in pelvis.
Evaluation
Evaluation consists of physical examination and radiographic 
imaging. Important clues as to the etiology of ascites come 
from analysis of the fluid itself.
Physical examination
Physical examination is not reliable for the diagnosis of 
ascites, especially in obese patients. Maneuvers used to detect 
ascites include testing for flank dullness, which if present 
is a reliable physical sign of ascites. Flank dullness, though, 
requires the presence of at least 1500 cc of fluid to be present 
for flank dullness to be detected. Overall, physical exam has 
less than optimal sensitivity and specificity.16
Imaging
Ultrasound
Ultrasound is one of the quickest screening tests for the 
detection of ascites. Ultrasound may detect as little as 100 cc 
of ascitic fluid.17
Computerized tomography
Computerized tomography can also detect ascites and also 
plays an important role for the cancer patient by providing 
an estimate of overall disease burden, and is capable of 
  determination of   disease progression.18 The determination Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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of disease progression may influence approaches to the 
management of malignant ascites.
Plain films
Plain films show a ground glass appearance and can suggest 
the presence of ascites.
Ascitic fluid analysis
Visual inspection
Gross observation of the fluid can provide some clues to the 
  etiology of ascites. Grossly bloody fluid is consistent with 
malignancy.18 Bleeding in the peritoneal cavity can be seen with 
hepatocellular carcinoma.19 Cloudy fluid suggests   infection. 
Milky fluid suggests chylous ascites.20 Chylous ascites has a 
trigylceride content of .200 mg/dL. Chylous ascites is often 
associated with malignancy, especially lymphoma.
Chemical analysis of ascitic fluid
Dividing ascitic fluid into the transudate and exudate 
  categories, such as is done with malignant pleural effusions 
using lactate dehydrogenase (LDH), protein and the ratios of 
these values (serum to ascites) has not proven to be beneficial 
for malignant ascites. One test of the fluid that has been useful 
for distinguishing malignant from cirrhotic causes of ascites 
is the serum-to-ascites albumin gradient.
Serum to ascites albumin gradient
The serum-to-ascites albumin gradient is especially useful when 
the etiology of ascites is in doubt, such as in the case of a patient 
with new onset ascites, or new ascites that occurs in the setting 
of liver cirrhosis. A gradient greater than or equal to 1.1 g/dL 
indicates portal hypertension with 97% accuracy, whereas a 
lower gradient (high-protein ascites) indicates a lack of portal 
hypertension and possibly the presence of a malignancy.21
Cytology
The presence of malignant cells in the ascitic fluid confirms the 
diagnosis of malignancy with a specificity of 100% and is the 
gold standard for the diagnosis. Cellular content of ascitic 
fluid represents shedding of tumor cells from the tumor into 
the peritoneal fluid. The yield of cytology is greater with pri-
mary peritoneal tumors.19 The sensitivity of cytology is only 
60%, as not all tumors shed cells into the peritoneum.22
Immunohistochemistry
Immunochemistry can help distinguish cancer cells from 
nonmalignant cells such as mesenchymal cells.23 Immuno-
histochemical techniques have not replaced cytology as the 
gold standard for the diagnosis of malignant ascites.
Prognosis
The presence of malignant ascites has a strong   negative 
  prognostic import; however, there are differences in   prognosis 
when individual malignancies are considered. One retrospective 
study reviewed experience with malignant ascites over 10 years.5 
The gastrointestinal malignancies associated with the poorest 
prognosis were gastric carcinoma (associated with a median 
survival of 1.4 months), colon cancer (with a median survival 
of 3.7 months), and pancreatic cancer (with a median survival of 
1.4 months). The study found that ascites of ovarian origin has a 
better median survival than all other cancer groups, which is in 
agreement with previous studies.13 In addition to origin of malig-
nancy as being prognostically important, other factors such as 
low serum albumin, can be independent prognostic factors, espe-
cially in the nonovarian cancer groups.24 Other factors important 
in prognosis of malignant ascites in nonovarian cancer groups 
include liver metastases, and elevated serum bilirubin.25
Management
Symptomatic management  
by paracentesis
Paracentesis can result in rapid symptom control in 90% of 
patients.26 One major concern is how much and how fast fluid 
can be removed. There is no agreement on the optimal rate 
of fluid removal, with no reports of increased adverse effects 
associated with a rapid rate of paracentesis. Concern exists 
that large volume fluid removal may lead to renal impairment 
and hypotension. In response to these concerns, which are well 
documented in the nonmalignant liver disease population, two 
studies have suggested that large volume paracentesis in malig-
nant ascites can be performed without complication. In both 
studies, large volumes of ascitic fluid were removed without 
the routine need for correction of hypovolemia.27,28 Paracente-
sis can be done safely in the presence of coagulopathy.29 There 
is no evidence for benefit with the use of albumin infusions 
for patients with malignant ascites as a means of maintaining 
intravascular volume after large volume paracentesis.30
Complications of paracentesis
Besides concerns about hypovolemia after large volume 
paracentesis, other concerns are for infection and rarely, 
  pulmonary embolization.31 There is a risk of   hypoalbuminemia 
with repeated paracentesis.32
Diuretics
There is a lack of randomized trials to assess the efficacy 
of diuretics in malignant ascites.33 Uncontrolled trials show 
an average response rate of 44% when diuretics are used in Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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malignant ascites.34–37 Responses have been identified in those 
with increased renin values, as well as elevated serum-ascites 
albumin gradient (SAAG) suggesting a likely response when 
there are characteristics of nonmalignant liver disease   present, 
which can occur in patients with malignant ascites.
Peritoneal-venous shunting
Shunts function as a connection between the peritoneal   cavity 
and large venous vessels, such as the vena cava, allowing escape 
of the peritoneal fluid back into the   circulation. Two types of 
shunts are available, the LeVeen and the Denver shunt.38 Both 
shunts direct ascitic fluid into the vena cava through a one-way 
valve. Higher pressures to achieve increased flow are achievable 
with the LeVeen shunt. Both types of shunts were designed to 
prevent repeated   paracentesis and prevent protein loss that can 
occur with repeated   paracentesis.37 Shunts palliate symptoms 
in 70% of patients.37,39–41 Complications associated with shunt 
  placement include disseminated intravascular coagulation, post-
operative   pulmonary edema, fever, and infection.42 Shunting is 
contraindicated in patients with fulminant hepatic failure and 
active   disseminated intravascular coagulation (DIC).42 Shunting 
is relatively contraindicated in patients with   positive cytology.42 
Shunt block occurs more often in the patients with positive 
  cytology and the shunt tends to   function longer in the patient 
with cytologically negative fluid.42 The median shunt survival 
in patients with   negative cytology was 140 days compared 
with 26 days in the positive group.42 High ascitic fluid protein 
and hemorrhagic effusions also lead to increased risk for shunt 
block.42 The overall incidence of shunt block is   approximately 
2%.   Volume overload occurs in 10%–16% of cases. Another 
unproven concern is the   dissemination of tumor cells throughout 
the body.3 The implication is that the disease can be worsened, 
as the patients for whom this procedure is used have advanced 
disease by virtue of   having malignant ascites. Fever is another 
complication that must be distinguished from active infection. 
True fever   associated with shunting is transient.43 There have 
been no successful studies comparing the superiority of one 
shunt type over the other in malignant ascites. Parsons and 
  associates demonstrated no survival or quality-of-life advantage 
when peritoneovenous shunting was compared with repeated 
  paracentesis.24 Shunts may not be an optimal option in patients 
with gastrointestinal   malignancies, as the response rates for 
symptom control are inferior to those with shunts associated 
with malignant ascites and ovarian and breast cancer.13,44
Catheter drainage
Catheter drainage remains an important option for the patient 
with malignant ascites. Advantages include easy drainage, 
and patient self-drainage.45 Catheters eliminate frequent 
trips to the hospital, the avoidance of procedural discomfort 
from repeated paracentesis, and enhance autonomy for the 
patient. Concerns about catheter drainage have included 
infection, protein loss, and technical complications such 
as catheter dislodgment and blockage. Types of catheters 
include the simple catheter, tunneled catheters, percutane-
ously placed peritoneal ports, modified venous access ports, 
and the PleurX catheter.46 The PleurX catheter was FDA 
approved for the management of malignant ascites in 2005.47 
There have been no comparisons of one catheter type versus 
another. Whatever the method of drainage, large volume 
paracentesis (.500 cc) can be done. Infection risk with the 
use of drainage catheters is complicated by small numbers 
of published data and lack of comparisons between catheter 
types.46 Peritonitis has been associated with catheter use, 
but it is unclear if peritonitis is directly related to catheter 
insertion. There is no data regarding superiority of one 
catheter type versus another with regards to incidence of 
dislodgement, leakage, blockage, or infection. Noncuffed 
catheters may be associated with a higher infection rate.46 
The incidence of infection with drainage catheters, such as 
the PleurX catheter, has been a cause for concern. A recent 
retrospective review of the literature found that in 221 ± 19 
patients with malignant ascites requiring catheter place-
ment, a higher incidence of infection was associated with 
untunneled catheters.2,46 Estimates of infection rates with 
untunneled catheters are approximately 11%.2 There is no 
data as to the exact degree of protein loss that occurs with 
catheter drainage, and whether or not that catheter-related 
protein loss is associated with worsening symptoms. There 
is no opinion on how loculation of peritoneal fluid affects 
performance of catheter placement or its success.
New approaches to malignant 
ascites
Octreotide
Octreotide, a somatostatin analog given for the management 
of malignant bowel obstruction, acts as an antisecretory agent 
and was found in a case series to successfully reduce ascites.48 
This has not been evaluated further.
Anti-VEGF therapy
The use of inhibitors of the tyrosine kinase activity of VEGF 
has been shown to inhibit formation of ascites in cell lines 
and animal models.49,50 Unfortunately there have been are no 
human studies at this time with this modality.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Metalloproteinase inhibitors
Human studies have been conducted with metalloproteinase 
inhibitors such as batimastat.51 In a phase I study, 22 patients 
with malignant ascites (16 patients with ovarian cancer, 
two patients with sarcoma, one patient with breast cancer, one 
patient with renal carcinoma, one patient with colon cancer, 
and one patient with endometrial cancer) had   batimastat 
instilled into the peritoneal cavity after paracentesis. No 
reaccumulation of ascites occurred after that single dose 
in five of the 23 patients, and these five survived for up to 
112 days. Seven other patients died without reaccumulation 
during this follow-up period. The major adverse effect in the 
first 24 hours was nausea and vomiting.
Immunologic therapies
Intraperitoneal immunotherapy
Interferon
Immunotherapy, via activation of patients’ cellular   immunity, 
has been used in ovarian carcinoma for the treatment of 
  malignant ascites. Intraperitoneal interferon is capable of 
stopping ascitic fluid production in ovarian cancer. One small 
study52 of 10 patients showed resolution of ascites in 3/10 when 
interferon is given intraperitoneally to patients with ovarian 
cancer. Parenteral interferon was studied in five patients, with 
2/5 having cessation of ascitic fluid production.53
Tumor necrosis factor-α
Tumor necrosis factor-α (TNF-α) has also been reported to be 
an effective palliative treatment for malignant ascites.54 In that 
study of 29 patients with refractory malignant ascites (10 with 
ovarian cancer, two with breast cancer, five with colorectal 
cancer, six with gastric cancer, four with pancreatic cancer, 
one with hepatic cancer, and one with endometrial cancer), 
22 responded to intraperitoneal TNF-α administration. Of 
these 22, 16 had complete and six had partial resolution of 
their ascites. The response seemed to predominate in patients 
with nonbulky distribution of tumor in the abdomen. Adverse 
effects of fever, chills, nausea, vomiting, and fatigue were 
reported, but these were generally well tolerated.
New immunologic approaches: new 
targets
New therapeutic approaches to the management of malignant 
ascites have taken advantage of new basic science about cancer 
cells and advances in the technology of monoclonal antibody 
therapy. One important discovery is that cellular adhesion 
molecules are overexpressed in several malignancies and thus 
have become a target for the advanced monoclonal antibody 
technology. One cellular adhesion protein called epithelial 
cell adhesion molecule (EpCAM) is a 40 kDa cell surface 
glycoprotein that mediates epithelium-specific, homotypic cell 
to cell adhesion on normal cells.55,56 EpCAM is a significant 
tumor antigen because its overexpression has been observed in a 
majority of carcinomas including ovarian cancer, breast cancer, 
prostate cancer, and nonsmall cell lung cancer.56 The inhibi-
tion of this antigen has been associated with a decrease in the 
proliferation, migration, and invasion of cancer cells, therefore 
making it an important target for cancer immunotherapy.
Trifunctional antibodies
Trifunctional antibodies have a much higher   capacity for tumor 
kill than previous monoclonal antibody lines.57   Preclinical 
models have shown that the improved   effectiveness of these 
antibodies lies in the ability of the fragment crystallizable (Fc) 
and fragment antigen-binding (Fab) portions of the antibody to 
trigger an immune response by interacting with EpCAM and 
the cluster of differentiation (CD) 3. The trifunctional molecule 
can induce and recruit T cells, as well as Fcγ-receptor+ accessory 
cells. Accessory cells are activated by an interaction between the 
Fc region of the intact antibody and Fcγ receptors.58 This activa-
tion of accessory cells leads to the secretion of cytokines such as 
IL-12, TNF-α, and the DC-specific cytokine DC-CK1, as well 
as to the presentation of costimulatory molecules to the T cell.57 
The formation of this complex induces the activation of differ-
ent classes of effector T cells,   resulting in excellent   antitumor 
activity. Another result of this process of immune activation is 
that tumor material is phagocytosed,58 processed, and presented 
by professional antigen-presenting cells .
Catumaxomab is one such trifunctional antibody.   Clinically 
the efficacy of these trifunctional molecules to generate antitu-
mor immunity was shown in patients with gastric carcinoma 
(N = 9), administered infusions of either catumaxomab or 
ertumaxomab. Four weeks later the patients were given irra-
diated tumor cells and were able to mount a significant T cell 
response to these cells in five of nine patients.59
Catumaxomab: clinical trials
Malignant pleural effusions
Catumaxomab was evaluated in a phase I/II trial in patients 
with malignant pleural effusion (MPE).55 Patients were given 
a series of three escalating doses of 5–200 µg   catumaxomab 
  administered intrapleurally. Patients had   effusions with cells 
positive for containing epithelial cell adhesion   molecule-positive 
cells. Twenty-four (11 breast, six lung [non-small cell lung car-
cinoma (NSCLC)], three   stomach, one ovarian, one carcinoma Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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of unknown primary, one esophageal) patients were treated 
with catumaxomab. Seven out of 24 patients (29%) treated 
with catumaxomab reached the end of trial. Attrition was due to 
death from advanced malignancy. Five of these seven patients 
showed a response to treatment according to the criteria. This 
included one complete response and four partial responses. 
A   complete response was defined as relief of symptoms related 
to the effusion with absence of fluid reaccumulation on chest 
radiographs. Partial response was defined as diminution of 
dyspnea related to the effusion, with partial reaccumulation 
of fluid (,50% of the initial radiographic evidence of fluid), 
with no further therapeutic thoracenteses required. Two patients 
had a treatment failure and these were patients with NSCLC. 
All responses to treatment were observed in patients with 
breast cancer. Most frequent adverse events were pyrexia, 
elevated liver enzymes, nausea, and decreased lymphocytes. 
  Dose-limiting toxicities were observed in two patients: one 
had pleural empyema and fatal sepsis, and one had grade three 
erythema and hepatobiliary disorder. Table 1 summarizes the 
therapy related adverse effects.
Malignant ascites
Catumaxomab was evaluated as part of a phase I/II dose-
escalating study for intraperitoneal application in patients 
with ovarian cancer who had EpCAM-positive tumor 
cells.60 Twenty-three women with recurrent ascites due 
to pretreated refractory ovarian cancer were treated with 
4–5 intraperitoneal infusions of catumaxomab in doses of 
10 to 200   micrograms within 9–13 days with loading doses 
of 5–10 µg. The maximum tolerated dose was defined at 10, 
20, 50, 200, and 200 µg for the first through fifth doses. In 
dose group IIa, one patient had a grade three serum bilirubin 
increase after the application of 50 µg. Therefore, the DSB 
decided to reduce this second dose to 20 µg, and the protocol 
was amended accordingly. Side effects included transient 
fever (83%), nausea (61%), and vomiting (57%), which were 
considered either grade one or two in severity. A total of 39 
grade three, and two grade 4, treatment-related adverse events 
(AE), nine of them after the highest dose level (200 µg), were 
observed in 16 patients. Most adverse effects were reversible 
without sequelae. Table 2 summarizes the AEs. Treatment 
with catumaxomab resulted in significant and sustained 
reduction of ascites flow rate. A total of 22 of 23 patients 
did not require paracentesis between the last infusion and 
the end of study one month later. Tumor cell monitoring 
revealed a reduction of EpCAM-positive   malignant cells in 
ascites by up to five log.
Adverse effects of catumaxomab
The adverse effects of catumaxomab have been found to be 
mainly secondary to cytokine release. These include nausea, 
vomiting, abdominal pain, pyrexia, and skin   reactions.4 
  Laboratory abnormalities have included elevated liver enzymes 
and lymphocytopenia. In the phase I/II   intraperitoneal trial by 
Burges and co-workers,60 fever (83%) was the predominant 
AE; other AEs included nausea (61%), vomiting (57%), 
-and abdominal pain (37%). Most of these adverse effects 
occurred on the day of or the day after   infusion and were fully 
reversible.60 Liver function abnormalities of gamma-glutamyl 
transpeptidase (GGT) and aspartate   aminotransferase (AST) 
occurred 13% and 9% respectively. Hematologic toxicity was 
characterized by   lymphocytopenia in 26%. No data on anemia 
was   available. Grade three   toxicities included fever, and liver 
function abnormalities. Two grade four toxicities included 
GGT increase and one case of hyperuricemia. In the pleural 
  effusion study55 where the drug was given intrapleurally, the 
most common   toxicities were pyrexia and hepatobiliary dis-
orders. Fever was no greater than grade two and was observed 
in 15 out of 24 patients, with six patients each having fever in 
dose levels II (10–50 µg) and III (20–100 µg). Hepatobiliary 
disorders were observed in the majority of patients and most 
Table 1 Adverse effects of catumaxomab: pleural effusion trial
Clinical/
laboratory 
adverse effect
Dose level 1 
N = 3 
Grade  
1/2/3/4
Dose level 2 
N = 15 
Grade  
1/2/3/4
Dose level 3 
N = 6 
Grade 
1/2/3/4
ALT  1/-/-/- 5/2/2/- 1/3/1/-
AST 1/-/-/- 5/3/1/- 1/1/3/-
γGGT 2/1/-/- 2/3/7/2 1/2/3/-
Bilirubin  1/-/-/- 3/1/-/- 1/3/1/-
Lymphopenia  -/1/1/- -/6/4/- -/2/4/-
Fever  2/1/-/- 5/1/-/- 3/3/-/-
Notes: Adapted from Sebastian M, Kiewe P, Schuette W, et al. Treatment of mali-
gnant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-
EpCAM × Anti-CD3): results of a phase I/II study. J Immunother. 2009;32(2):195–202.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransfease; γGGT, 
γ glutamyl transeferase. 
Table 2 Malignant ascites trial: grade three or greater toxicities
Symptom Number of patients level
Fever 1
Vomiting  1
Blood alkaline phosphatase increased 4
γ-GGT increased 2
AST increased 1
Hyperbilirubinemia 2
Notes: Adapted from Burges A, Wimberger P, Kumper C, et al. Effective relief of 
malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM 
× anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007;13(13):3899–3905.
Abbreviations: AST, aspartate aminotransfease; γGGT, γ glutamyl transeferase.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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(13 of 14 events) were considered catumaxomab related. The 
mean values of GGT, alanine aminotransferase (ALT), AST, 
and bilirubin showed a transient increase 24 hours after the 
first and second infusion. The increase in the majority of cases 
did not exceed grade two and was highest after the second 
infusion. There was no dose response relationship. Grade 
three and four elevations of GGT occurred in nine (60%) and 
three (50%) patients in dose levels II and III, respectively. No 
grade four elevation of AST or ALT was observed. In one 
and three patients at dose levels II and III, respectively, grade 
three elevations of AST occurred. Two patients developed 
grades three and four elevation of GGT in the follow-up 
period 8 days after the third infusion; in one of the cases, a 
relationship to the study drug could not be ruled out by the 
investigator. Both patients had systemic progression of disease 
as possible explanation for the GGT elevation. Hematologic 
toxicity was primarily anemia and lymphopenia. Seven of 
15 patients in dose level II (10–50 µg) and two of six patients 
in dose level III (20–100 µg) had grade two anemia.55
Administration of catumaxomab
Experience with catumaxomab given systemically suggests 
that premedication with 1000 mg paracetamol (orally or 
  suppository) and use of an H1 and H2 blocker be used to mini-
mize febrile reactions and minimize risk for anaphylaxis.55,60 In 
the pleural effusion study 100 mL 0.9% NaCl solution was also 
infused into the pleural space via the infusion lumen of the tro-
car catheter to help disperse antibody. In the malignant ascites 
study60 1,000 mg paracetamol was given 30 minutes before the 
start of infusion. To improve the catumaxomab distribution 
within the peritoneal cavity, 500 mL of 0.9% NaCl solution 
was administered intraperitoneally 30 minutes before the start 
of the catumaxomab infusion to disperse the antibody.
Conclusion
The use of trifunctional antibodies represents a new approach 
to the management of two important complications associated 
with advanced cancer, namely, malignant pleural effusions and 
malignant ascites. The effectiveness of catumaxomab in terms 
of markers of palliation such as decreased need for paracentesis 
and thoracentesis is evident even in the early studies with this tri-
functional antibody. The toxicities experienced by the patients in 
these studies, while partly attributable to the antibody itself, may 
also be evidence of the rapid tumor   progression in this patient 
population. The harnessing of the immune system suggests that 
this antibody may not only be effective for advanced disease but 
may also be beneficial for patients with earlier stages of disease. 
The analogy would be the use of   rituximab in conjunction with 
chemotherapy to improve survival in patients with lymphoma. 
Further work in a broad spectrum of EpCam-positive tumors 
may very well bear witness to the effectiveness of this unique 
molecular therapy.
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